Ann: Bisantrene cGMP API Manufacturing Completed at Laurus Labs, page-47

There's been a lot of complaining about clinical delays of late. These delays were apparent 18 months ago.

The strategy released in March 2022 aimed to develop the cardioprotection and FTO opportunities to POC and then transact.

This is still achievable.

Multiple value inflection points along the way - i.e. the potential for Sheba 2.0 data (imminent) to result in the license of AML/RC110 as an example. The notion that the company will be unable to deliver upside to shareholders until a transaction occurs is a false narrative.